Initial orders from such prestigious institutions as Ronald Reagan UCLA Medical Center and Rady Children's Hospital not only validate the demand and potential efficacy of Catheter Precision, Inc.'s LockeT but also suggest a positive outlook for VTAK's revenue and market penetration in the healthcare sector. This development could attract investor interest and positively influence VTAK's stock price in the short term.